Brian Allee, DO
Family Medicine · Pauls Valley, OKNPI 1952340572
Payments from drug & device makers
Across 176 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$814
- Lilly USA, LLC$474
- AbbVie$386
- Novo Nordisk$378
- Sanofi-aventis U.S. LLC$175
- Merck$125
- plus $730 from 19 others
What the payments were for
- Food & beverage$2,97597%
- Education$1063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $814 |
| Lilly USA, LLC | 35 | $474 |
| AbbVie(2 entities) | 22 | $386 |
| Novo Nordisk | 26 | $378 |
| Sanofi-aventis U.S. LLC | 9 | $175 |
| Merck | 10 | $125 |
| Astellas Pharma US Inc | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $96 |
| Pfizer | 5 | $85 |
| Boehringer Ingelheim | 4 | $68 |
| Exact Sciences | 4 | $61 |
| Bayer | 3 | $49 |
| Organon | 3 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 2 | $24 |
| Mylan Specialty L.p. | 2 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,081 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $120,888 |
| MounjaroTirzepatide | 102 | $110,349 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $76,491 |
| JardianceEmpagliflozin | 66 | $72,354 |
| EliquisApixaban | 102 | $68,263 |
| FarxigaDapagliflozin Propanediol | 56 | $50,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $47,198 |
| TrulicityDulaglutide | 26 | $33,303 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $15,946 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $13,928 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,082 |
| Omeprazole | 393 | $7,423 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 219 | $7,141 |
| Atorvastatin Calcium | 398 | $6,101 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $474 | $143,653128 claims |
| Novo NordiskOzempic | $378 | $120,888107 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $175 | $76,49160 claims |
| Boehringer IngelheimJardiance | $68 | $72,35466 claims |
| PfizerEliquis | $85 | $68,263102 claims |
| AstraZenecaFarxiga | $814 | $50,34456 claims |
| GSKTrelegy Ellipta | $13 | $47,19859 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $96 | $5,87212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Pauls Valley
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.